Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TCTA
REST API REST API
Homo sapiens
TCTA is differentially expressed in 228 experiments: 101 organism parts: cerebellum, prostate, ... (99 more);, 120 disease states: normal, prostate carcinoma, ... (118 more);, 61 cell types 350 cell lines 27 compound treatments and 63 other conditions.
Orthologs Tcta (Mus musculus)   tcta (Danio rerio)   TCTA_BOVIN (Bos taurus)   tcta (Xenopus laevis)   TCTA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term membrane, integral to membrane
InterPro Term T-cell_leukemia_transloc-assoc
UniProt Accession P57738
Search EB-eye ENSG00000145022
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (32 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SW480
1
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37, E-GEOD-2509
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HepG2
2
E-MTAB-37, E-GEOD-7307
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
MDAMB453
2
E-MTAB-37, E-MTAB-62
344 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-GEOD-13909, E-GEOD-4219, E-GEOD-13987, ... (30 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3204, E-GEOD-3920
CD34+
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
NK cell
1
E-GEOD-3982
induced pluripotent stem cell
1
E-GEOD-18147
intrathymic T progenitor cell
1
E-GEOD-1460
55 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-882, E-GEOD-22148, ... (36 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-96
colon cancer
1
E-MTAB-62
polycystic ovarian syndrome
1
E-MTAB-62
114 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-5741, E-GEOD-3720, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
none
2
4
E-TABM-868, E-MEXP-2285, E-GEOD-412, E-MEXP-1958, E-GEOD-6907, ... (6 experiments)
nocodazole
2
E-GEOD-6431, E-GEOD-571
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
mercury dichloride
1
E-GEOD-6907
M-CSF
1
E-GEOD-5099
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-4667, E-MTAB-62

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-1045, E-GEOD-3494, E-GEOD-22593, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-22541, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-21909, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.314 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM